- Home
- ACIC vs AUTL Comparison
ACIC vs AUTL Comparison
Compare ACIC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- AUTL
- Stock Information
- Founded
- ACIC 1999
- AUTL 2014
- Country
- ACIC United States
- AUTL United Kingdom
- Employees
- ACIC N/A
- AUTL N/A
- Industry
- ACIC Property-Casualty Insurers
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACIC Finance
- AUTL Health Care
- Exchange
- ACIC Nasdaq
- AUTL Nasdaq
- Market Cap
- ACIC 588.1M
- AUTL 590.8M
- IPO Year
- ACIC N/A
- AUTL 2018
- Fundamental
- Price
- ACIC $12.36
- AUTL $2.37
- Analyst Decision
- ACIC Buy
- AUTL Strong Buy
- Analyst Count
- ACIC 1
- AUTL 3
- Target Price
- ACIC $16.00
- AUTL $10.20
- AVG Volume (30 Days)
- ACIC 172.8K
- AUTL 1.2M
- Earning Date
- ACIC 02-27-2025
- AUTL 03-13-2025
- Dividend Yield
- ACIC 4.04%
- AUTL N/A
- EPS Growth
- ACIC N/A
- AUTL N/A
- EPS
- ACIC 1.76
- AUTL N/A
- Revenue
- ACIC $290,784,000.00
- AUTL $10,091,000.00
- Revenue This Year
- ACIC N/A
- AUTL $851.83
- Revenue Next Year
- ACIC $12.68
- AUTL $264.18
- P/E Ratio
- ACIC $7.00
- AUTL N/A
- Revenue Growth
- ACIC 1.02
- AUTL 82.71
- 52 Week Low
- ACIC $8.82
- AUTL $2.07
- 52 Week High
- ACIC $15.08
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- ACIC 45.88
- AUTL 46.88
- Support Level
- ACIC $11.89
- AUTL $2.12
- Resistance Level
- ACIC $12.41
- AUTL $2.38
- Average True Range (ATR)
- ACIC 0.43
- AUTL 0.13
- MACD
- ACIC 0.01
- AUTL 0.02
- Stochastic Oscillator
- ACIC 60.16
- AUTL 37.23
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary. The company has two segments namely: Commercial Lines Business and Personal Lines Business. It derives maximum revenue from Commercial Lines Business Segment.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.